Financial Performance and Subsidiaries Revenue
KEY HIGHLIGHTS
Diversified enterprise focused in pharmaceutical sector with presence across geographies - India, US and ROW.
Strong brand position in domestic pharma segments
• Well established player in oncology with brands catering to diseases including breast, bone, lung and ovarian cancer
• Expanding reach to wider pool of doctors through NATCO REACH
Focused on complex generics for the US Markets with niche Para IV and Para III filings
.
Established front-end presence through Dash acquisition.
Two R&D centers with around 465 employees (1)
Targeting growth in Crop Health Sciences business with state-of-the-art manufacturing facilities for both technical and formulation
Total revenues (2) of 28,117 million for the financial year ended 31st March 2023
Listed on BSE and NSE with a market capitalisation (3) of USD 1.51 billion
Incorporated in 1981 and headquartered in Hyderabad with around 4,900 employees across all locations (1)
(1) As of March 31, 2023
(2) Represents consolidated revenue
(3) Market capitalization as of June 30, 2023 using INR / USD exchange rate of *82.0428
NATCO
3View entire presentation